GDTC — CytoMed Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual cashflow statement for CytoMed Therapeutics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.

	2019 December 31st	C2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS/A	PROSPECTUS/A	PROSPECTUS/A	20-F	20-F
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-0.851	-1.94	-2.05	-3.13	-4.13
Depreciation
Amortisation
Non-Cash Items	0.029	0.678	0.375	1.23	0.117
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	0.01	0.116	-0.366	0.112	0.202
Change in Accounts Receivable
Change in Inventories
Change in Payable / Accrued Expenses
Other Operating Cash Flow
Cash from Operating Activities	-0.635	-0.849	-1.71	-1.4	-3.43
Capital Expenditures	-1.17	-0.265	-0.582	-0.474	-0.058
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	0	-0.248	-0.241	0	-2.77
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-1.17	-0.513	-0.824	-0.473	-2.83
Financing Cash Flow Items	-0.027	-0.106	1.88	-0.125	-0.047
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	1.19	1.88	4.17	0.969	10.9
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-0.616	0.514	1.63	-0.933	4.64